This study demonstrates that long-term mineralocorticoid receptor blockade with spironolactone decreased coronary TRPC expression, atherosclerosis, and hypercontractility in the Ossabaw pig model of metabolic syndrome without impacting obesity or glucose tolerance. This evidence concerns the gene NR3C2 and atherosclerosis.